Randomized phase III trial of adjuvant chemotherapy with gemcitabine vs S-1 in patients with resected pancreatic cancer
Latest Information Update: 12 Jun 2020
Price :
$35 *
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Carcinoma; Ductal carcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 May 2020 Results of a pooled analysis from four phase III trials: CONKO-001, JASPAC-01, ESPAC-4 and PRODIGE assessing prolongation of average survival time, prolongation of average event free time and time lived without an event presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 01 Feb 2020 Results of a retrospective biomarker study published in the Cancer Science.
- 22 Feb 2018 Results (n=354) assessing health-related quality of life with of S-1 versus gemcitabine in patients with pancreatic cancer published in the European Journal of Cancer.